The antitumor activity of umbelliferone in human renal cell carcinoma via regulation of the p110γ catalytic subunit of PI3Kγ
Umbelliferone exhibits extensive pharmacological activity, including anti-immunomodulatory, anti-inflammatory and antigenotoxicity activities. However, its antitumor properties still remain unclear in human renal cell carcinoma (RCC) cells. Our results have revealed that treatment of human RCC cells...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2019-03-01
|
| Series: | Acta Pharmaceutica |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/acph-2019-0004 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832570509211992064 |
|---|---|
| author | Wang Xue Huang Shuaishuai Xin Xia Ren Yu Weng Guobin Wang Ping |
| author_facet | Wang Xue Huang Shuaishuai Xin Xia Ren Yu Weng Guobin Wang Ping |
| author_sort | Wang Xue |
| collection | DOAJ |
| description | Umbelliferone exhibits extensive pharmacological activity, including anti-immunomodulatory, anti-inflammatory and antigenotoxicity activities. However, its antitumor properties still remain unclear in human renal cell carcinoma (RCC) cells. Our results have revealed that treatment of human RCC cells (786-O, OS-RC-2, and ACHN) with umbelliferone reduced cell proliferation in a concentration-dependent manner and induced dose-dependent apoptotic events. In addition, cell cycle analysis determined that umbelliferone treatment induced cell cycle arrest in the G1 phase in a dose-dependent manner. Furthermore, western blotting analysis showed a dose-dependent decrease in Ki67, MCM2, Bcl-2, CDK2, CyclinE1, CDK4, and CyclinD1 and a dose-dependent increase in Bax in RCC cells cultured with umbelliferone. Similarly, umbelliferone exhibited a dose-dependent reduction of p110γ when using western blotting analyses. Taken together, these results provide an insight into the pharmacology regarding the potential application of umbelliferone, which contributes to cell death by decreasing p110γ protein expression. |
| format | Article |
| id | doaj-art-8352fdb7775446c3977d72ddfe1e98f9 |
| institution | Kabale University |
| issn | 1846-9558 |
| language | English |
| publishDate | 2019-03-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Acta Pharmaceutica |
| spelling | doaj-art-8352fdb7775446c3977d72ddfe1e98f92025-02-02T15:22:11ZengSciendoActa Pharmaceutica1846-95582019-03-0169111111910.2478/acph-2019-0004acph-2019-0004The antitumor activity of umbelliferone in human renal cell carcinoma via regulation of the p110γ catalytic subunit of PI3KγWang Xue0Huang Shuaishuai1Xin Xia2Ren Yu3Weng Guobin4Wang Ping5Department of Urologic Surgery, Ningbo Urology and Nephrology Hospital, Ningbo315000, ChinaDepartment of Urologic Surgery, Ningbo Urology and Nephrology Hospital, Ningbo315000, ChinaDepartment of Urologic Surgery, Ningbo Urology and Nephrology Hospital, Ningbo315000, ChinaDepartment of Urologic Surgery, Ningbo Urology and Nephrology Hospital, Ningbo315000, ChinaDepartment of Urologic Surgery, Ningbo Urology and Nephrology Hospital, Ningbo315000, ChinaNingbo University, School of Medicine, Ningbo315211, ChinaUmbelliferone exhibits extensive pharmacological activity, including anti-immunomodulatory, anti-inflammatory and antigenotoxicity activities. However, its antitumor properties still remain unclear in human renal cell carcinoma (RCC) cells. Our results have revealed that treatment of human RCC cells (786-O, OS-RC-2, and ACHN) with umbelliferone reduced cell proliferation in a concentration-dependent manner and induced dose-dependent apoptotic events. In addition, cell cycle analysis determined that umbelliferone treatment induced cell cycle arrest in the G1 phase in a dose-dependent manner. Furthermore, western blotting analysis showed a dose-dependent decrease in Ki67, MCM2, Bcl-2, CDK2, CyclinE1, CDK4, and CyclinD1 and a dose-dependent increase in Bax in RCC cells cultured with umbelliferone. Similarly, umbelliferone exhibited a dose-dependent reduction of p110γ when using western blotting analyses. Taken together, these results provide an insight into the pharmacology regarding the potential application of umbelliferone, which contributes to cell death by decreasing p110γ protein expression.https://doi.org/10.2478/acph-2019-0004umbelliferonerenal cell carcinomap110γanti-cancer activity |
| spellingShingle | Wang Xue Huang Shuaishuai Xin Xia Ren Yu Weng Guobin Wang Ping The antitumor activity of umbelliferone in human renal cell carcinoma via regulation of the p110γ catalytic subunit of PI3Kγ Acta Pharmaceutica umbelliferone renal cell carcinoma p110γ anti-cancer activity |
| title | The antitumor activity of umbelliferone in human renal cell carcinoma via regulation of the p110γ catalytic subunit of PI3Kγ |
| title_full | The antitumor activity of umbelliferone in human renal cell carcinoma via regulation of the p110γ catalytic subunit of PI3Kγ |
| title_fullStr | The antitumor activity of umbelliferone in human renal cell carcinoma via regulation of the p110γ catalytic subunit of PI3Kγ |
| title_full_unstemmed | The antitumor activity of umbelliferone in human renal cell carcinoma via regulation of the p110γ catalytic subunit of PI3Kγ |
| title_short | The antitumor activity of umbelliferone in human renal cell carcinoma via regulation of the p110γ catalytic subunit of PI3Kγ |
| title_sort | antitumor activity of umbelliferone in human renal cell carcinoma via regulation of the p110γ catalytic subunit of pi3kγ |
| topic | umbelliferone renal cell carcinoma p110γ anti-cancer activity |
| url | https://doi.org/10.2478/acph-2019-0004 |
| work_keys_str_mv | AT wangxue theantitumoractivityofumbelliferoneinhumanrenalcellcarcinomaviaregulationofthep110gcatalyticsubunitofpi3kg AT huangshuaishuai theantitumoractivityofumbelliferoneinhumanrenalcellcarcinomaviaregulationofthep110gcatalyticsubunitofpi3kg AT xinxia theantitumoractivityofumbelliferoneinhumanrenalcellcarcinomaviaregulationofthep110gcatalyticsubunitofpi3kg AT renyu theantitumoractivityofumbelliferoneinhumanrenalcellcarcinomaviaregulationofthep110gcatalyticsubunitofpi3kg AT wengguobin theantitumoractivityofumbelliferoneinhumanrenalcellcarcinomaviaregulationofthep110gcatalyticsubunitofpi3kg AT wangping theantitumoractivityofumbelliferoneinhumanrenalcellcarcinomaviaregulationofthep110gcatalyticsubunitofpi3kg AT wangxue antitumoractivityofumbelliferoneinhumanrenalcellcarcinomaviaregulationofthep110gcatalyticsubunitofpi3kg AT huangshuaishuai antitumoractivityofumbelliferoneinhumanrenalcellcarcinomaviaregulationofthep110gcatalyticsubunitofpi3kg AT xinxia antitumoractivityofumbelliferoneinhumanrenalcellcarcinomaviaregulationofthep110gcatalyticsubunitofpi3kg AT renyu antitumoractivityofumbelliferoneinhumanrenalcellcarcinomaviaregulationofthep110gcatalyticsubunitofpi3kg AT wengguobin antitumoractivityofumbelliferoneinhumanrenalcellcarcinomaviaregulationofthep110gcatalyticsubunitofpi3kg AT wangping antitumoractivityofumbelliferoneinhumanrenalcellcarcinomaviaregulationofthep110gcatalyticsubunitofpi3kg |